Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.
Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.